ArticleFrontiers in immunology2025
Precision prediction of intervertebral disc degeneration in ankylosing spondylitis using a nomogram model reveals the pivotal role of Th2-type immune dysregulation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gut-Intervertebral Disc Axis: Gut Microbiome-Driven Immune-Metabolic Imbalance and Intervertebral Disc Degeneration.Journal of cellular physiology · 2026Review
- Exploring the causal relationships between spondyloarthritis/ankylosing spondylitis and intervertebral disc degeneration: a bidirectional Mendelian randomization study.Journal of orthopaedic surgery and research · 2025Article
- Immune Mechanisms and Pain in Intervertebral Disc Degeneration.Journal of inflammation research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ankylosing spondylitis (AS) is an immune-mediated chronic inflammatory disease. When AS is complicated by intervertebral disc degeneration (IVDD), disease complexity increases substantially, often resulting in poor long-term outcomes. Although previous studies have explored the mechanisms linking AS and IVDD, reliable tools for precise risk prediction and early intervention remain scarce. Methods: In this retrospective study, we enrolled 144 patients with AS (60 with and 84 without IVDD). Their clinical features, immune status, and inflammatory cytokine levels were analyzed. A nomogram prediction model was constructed using multivariable logistic regression. Model performance was evaluated via receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA). Results: Multivariable analysis identified body mass index (BMI), peripheral blood Th2 cell percentage (Th2%), and serum IL-4 levels as independent risk factors for IVDD in patients with AS. All associations remained statistically significant after Benjamini-Hochberg correction (BMI: BH-adjusted P = 0.001; Th2%: BH-adjusted P = 0.019; IL-4: BH-adjusted P = 0.019). Incorporation of these factors into a nomogram yielded excellent discriminative performance (area under the curve, AUC = 0.83) and calibration, outperforming a simplified model based solely on BMI (AUC = 0.74). This improvement in predictive accuracy was statistically significant, as determined by DeLong's test (P = 0.018). DCA revealed that at a threshold probability of 60.8%, the nomogram effectively distinguished high-risk patients, underscoring its strong clinical applicability. Conclusions: This study is the first to highlight the critical roles of Th2 cells and IL-4 in AS complicated by IVDD, and establishes a nomogram that accurately predicts the risk of IVDD in AS. Beyond offering a tool for early detection and personalized management, these findings open avenues for investigating overlapping pathogenic mechanisms and potential immunotherapeutic targets in AS-IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.